Update on heart failure and diabetes: what is the potential role of semaglutide and the combination of GIP-GLP1 receptor agonists in the management of HF? episode artwork

EPISODE · Jan 7, 2025 · 7 MIN

Update on heart failure and diabetes: what is the potential role of semaglutide and the combination of GIP-GLP1 receptor agonists in the management of HF?

from CardioPractice Cardio Talk · host European Society of Cardiology

With Nikolaus Marx, Chair of Task Force of the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes, RWTH University Hospital Aachen, Aachen - Germany and Ruxandra Christodorescu, University of Medicine and Pharmacy Victor Babes, Timisoara - Romania. In this podcast, Nikolaus Marx joins Ruxandra Christodorescu to discuss updates on heart failure and diabetes: what is the potential role of semaglutide and the combination of GIP-GLP1 receptor agonists in the management of HF?

Episode metadata supplied by the publisher feed · Published Jan 7, 2025

Embed this episode

Ready to play

Update on heart failure and diabetes: what is the potential role of semaglutide and the combination of GIP-GLP1 receptor agonists in the management of HF?

0:00 7:28

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of CardioPractice Cardio Talk?

This episode is 7 minutes long.

When was this CardioPractice Cardio Talk episode published?

This episode was published on January 7, 2025.

Can I download this CardioPractice Cardio Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!